Clinical Trials Logo

Asthma clinical trials

View clinical trials related to Asthma.

Filter by:

NCT ID: NCT06453382 Active, not recruiting - Hypertension Clinical Trials

Development and Testing of a Sub-district Specific Model of 'Whole-of-government', and 'Whole-of-society' Approaches for the Prevention and Control of Non-communicable Diseases in a Sub-district of Bangladesh

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

Globally, non-communicable diseases (NCDs) are the leading cause of both mortality and morbidity. This intervention study aims to prevent and manage NCDs by adopting the World Health Organization's (WHO) comprehensive 'whole-of-government' and 'whole-of-society' approach. Although the Bangladesh government has devised a Multisectoral Action Plan (MAP) for NCD prevention and control, there's a need to operationalize these approaches at the sub-district level. This requires establishing a framework, implementing it, and assessing its effectiveness. To accomplish the study's objectives, the investigators will initially identify key stakeholders involved in NCD-related work or potentially able to contribute. Subsequently, investigators will qualitatively explore their potential involvement in NCD prevention and control, including their current roles and responsibilities, and how they could further contribute. Workshops will be conducted with these stakeholders to develop a tailored intervention model for NCD prevention and control at the sub-district level, utilizing the 'whole-of-government' and 'whole-of-society' approach. Following this, the sub-district specific model will be implemented, and the process will be documented. Finally, an evaluation will be conducted to assess the effectiveness of the sub-district specific model in achieving NCD-specific outcomes.

NCT ID: NCT06451328 Completed - Asthma Clinical Trials

Lignosus Rhinoceros TM02® as a Complementary Therapy for Uncontrolled Asthma

Start date: March 1, 2022
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn if TM02® works to treat partially controlled or uncontrolled asthma in adults. It will also learn about the efficacy and safety of TM02®. The main questions it aims to answer are: Does TM02® causes bronchodilation (to what extent), improves asthma control, and reduces airway inflammation and blood eosinophils and serum immunoglobulin E levels. Participants will: Take TM02® every day for 90 days. Visit the clinic once every 30 days for checkups, tests and to fill up questionnaires. Keep a diary of their symptoms and the number of times they use a rescue inhaler.

NCT ID: NCT06449859 Active, not recruiting - Asthma Clinical Trials

A Clinical Trial of TQC2938 Injection in Healthy Adult Subjects

Start date: June 13, 2023
Phase: Phase 1
Study type: Interventional

The study is designed in two phases: single-dose administration and multiple-dose administration. A randomized, double-blind, placebo-controlled trial design was used to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity of TQC2938 injection in healthy adults.

NCT ID: NCT06449573 Recruiting - Asthma Clinical Trials

Evaluation of Cardiopulmonary Parameters in Individuals With Asthma

Start date: March 1, 2024
Study type: Observational

The aim of the study compare the cardiopulmonary parameters of individuals with asthma with healthy subjects.

NCT ID: NCT06448585 Active, not recruiting - Rhinitis Clinical Trials

Dietary Supplement (Beta-Glucans) in Allergic Patients Undergoing Subcutaneous Immunotherapy.

Start date: May 20, 2024
Phase: Phase 4
Study type: Interventional

The present study will attempt to determine if the dietary supplement, based on a synergistic combination of β-glucans and Saccharomyces cerevisiae yeast enriched with Zinc and Selenium, can improve the immune response in allergic patients diagnosed with rhinitis or rhinoconjunctivitis, with or without controlled asthma, who are undergoing subcutaneous polymerized 100 immunotherapy with a rapid initiation protocol. It will also attempt to determine if the dietary supplement in combination with DAO enzyme could improve the immunological response to immunotherapy.

NCT ID: NCT06441812 Not yet recruiting - Clinical trials for Eosinophilic Asthma Patients

A Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients

Start date: June 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluation the long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients

NCT ID: NCT06438913 Not yet recruiting - Asthma Clinical Trials

Tezepelumab Treatment in Korean Severe Asthma Patients

Start date: June 12, 2024
Study type: Observational [Patient Registry]

There is no study that systematically evaluated the effect of Tezepelumab on cough, and based on this background, the present researchers aimed to evaluate the effect of Tezepelumab treatment in patients with severe asthma who complain of cough using the Leicester Cough Questionnaire, a cough-related quality of life measurement tool.

NCT ID: NCT06438757 Not yet recruiting - Allergic Asthma Clinical Trials

Trial of JYB1904 in Allergic Asthma

Start date: June 21, 2024
Phase: Phase 2
Study type: Interventional

This phase IIa trial is meant to evaluate the pharmacokinetics, pharmacodynamics and safety of JYB1904 in patients with allergic asthma.

NCT ID: NCT06437444 Recruiting - Asthma in Children Clinical Trials

Asthma Crisis in Paediatrics: Impact of a Care Pathway in Primary and Hospital Care

Start date: May 7, 2024
Phase: N/A
Study type: Interventional

This study aims to evaluate the effect of the implementation of the new Asthma Care Pathway in the Basque Healthcare Service for the improvement of care for children with asthma attacks and the reduction of variability between professionals and care settings in this care practice. Asthma is the most common chronic disease in children and has a major impact on people's quality of life. The Asthma Care Pathway is a structured multidisciplinary care plan that details the essential steps in the care of patients with mild-moderate asthma attacks and the coordinated practice of the agents involved as dictated by the evidence. This pathway will include quality indicators of compliance with diagnostic criteria, assessment of severity and prescription of drugs, as well as the experience of families and professionals, which have been collected in meetings designed for this purpose. The study consists in a mixed methods implementation trial with two phases: 1. Phase I: a quantitative evaluation will be carried out to assess implementation outcomes at the professional level through a pretest-posttest quasi-experimental study with paired control group, with a ratio of 1:2. The primary outcome variable will be the overall percentage of bronchodilator treatment with a spacer chamber in children diagnosed with mild-moderate asthma attacks. We will also include as outcomes to be measured the registration rate of the Pulmonary Score, the recording rate of the assessment of persistent asthma symptoms, and the rate of initiation of background treatment in children with persistent asthma symptoms. These variables will be analysed using differences in pre- and post-intervention outcome measures between the intervention and control groups. 2. Phase II: A qualitative evaluation will be carried out through a structured process with discussion groups focused on the identification of the main barriers and facilitators for the provision of recommended clinical practice related to asthmatic crisis in mild-moderate cases established by the Asthma Care Pathway. A purposive sample of paediatricians stratified by level of care and service organisations will be recruited to ensure that all views are represented in the discussion groups. The structured script will be designed with questions to explore each of the domains of the Theoretical Domains Framework (TDF). The study will be carried out mainly in two integrated healthcare organizations (IHO), which are made up of two primary care areas and the paediatric reference hospital emergency department of both areas, as well as the hospitalisation, intensive care and paediatric pneumology departments of said hospital, to extend in the future the Asthma Care Pathway to the rest of the Basque Health Service IHOs.

NCT ID: NCT06435273 Not yet recruiting - Asthma Clinical Trials

A Randomised, Double-blind, Parallel Group, Placebo Controlled, 4-Week, Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma

Start date: July 31, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the effect on airway inflammation and JAK1-associated signalling pathways of AZD4604 compared with placebo in participants with moderate-to-severe asthma. Study details include: - The study duration for each participant will be approximately 10 weeks. - The duration of IMP administration will be approximately 4 weeks.